Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 5,562 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Completed Phase 1 Interventional

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

NCT04095273
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 19, 2026, 10:59 PM EDT
Terminated Not applicable Interventional Results available

Comparative Research of Alzheimer's Disease Drugs

NCT01362686
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Donepezil, Galantamine, Rivastigmine
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Fishers, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 19, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)

NCT02033941
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Meganatural-Az Grapeseed Extract, Placebo
Drug
Lead sponsor
Hillel Grossman
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 19, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients

NCT04350177
View directory record Official record
Conditions
Healthy Elderly, Parkinson Disease
Interventions
IkT-148009, Placebo
Drug
Lead sponsor
ABLi Therapeutics, Inc.
Industry
Eligibility
55 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Long Beach, California • Hallandale, Florida • Farmington Hills, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 19, 2026, 10:59 PM EDT
Completed Phase 4 Interventional Results available

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

NCT01782222
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Oxnard, California • Ormond Beach, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 19, 2026, 10:59 PM EDT
Completed Phase 4 Interventional

Do HMG CoA Reductase Inhibitors Affect Abeta Levels?

NCT00303277
View directory record Official record
Conditions
Alzheimer's Disease, Aging
Interventions
simvastatin, pravastatin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2010 · Synced Oct 19, 2026, 10:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen D Pridopidine

NCT04615923
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 19, 2026, 10:59 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

NCT03945279
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB100, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 19, 2026, 10:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis

NCT03887273
View directory record Official record
Conditions
Transverse Myelitis
Interventions
Q-Cells
Biological
Lead sponsor
Q Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 19, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3002813 in Participants With Alzheimer's Disease

NCT01837641
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3002813-IV, LY3002813-SC, Placebo-IV
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
4
States / cities
Long Beach, California • Orlando, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 19, 2026, 10:59 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

NCT06021522
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Ecopipam
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
44
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 10:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Studies in Alzheimer's Disease

NCT00001235
View directory record Official record
Conditions
Alzheimer's Disease, Nervous System Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

NCT00279825
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Bingham Farms, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 19, 2026, 10:59 PM EDT
Terminated No phase listed Observational Results available

Brain Networks and Consciousness

NCT04502550
View directory record Official record
Conditions
Loss of Consciousness, Parkinson Disease, Essential Tremor, Anesthesia
Interventions
Propofol
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 19, 2026, 10:59 PM EDT
Not listed Not applicable Interventional

Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease

NCT01195389
View directory record Official record
Conditions
Alzheimer's Dementia
Interventions
Resonator
Device
Lead sponsor
pico-tesla Magnetic Therapies, LLC
Industry
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2011 · Synced Oct 19, 2026, 10:59 PM EDT
Completed No phase listed Observational

Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders

NCT00001220
View directory record Official record
Conditions
Deglutition Disorder, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 10:59 PM EDT
Recruiting Phase 2 Interventional

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420
View directory record Official record
Conditions
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG)
Interventions
Efgartigimod IV, Empasiprubart IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Carlsbad, California • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 10:59 PM EDT
Enrolling by invitation Not applicable Interventional

NAD Supplementation in Parkinson's Disease

NCT07703137
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Nicotinamide Riboside (NR), Oral placebo capsules
Dietary Supplement
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 19, 2026, 10:59 PM EDT
Active, not recruiting Phase 2 Interventional

T-regulatory Cells in ALS

NCT04055623
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 19, 2026, 10:59 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The PorchLight Project

NCT05550727
View directory record Official record
Conditions
Memory Loss, Alzheimer Disease, Dementia
Interventions
PorchLight
Other
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 10:59 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

NCT05086094
View directory record Official record
Conditions
Multiple System Atrophy (MSA)
Interventions
BHV3241, verdiperstat
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 19, 2026, 10:59 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients

NCT06432166
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
2-hydroxybenzylamine acetate, Placebo
Drug · Other
Lead sponsor
MTI Biotech Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 10:59 PM EDT
Withdrawn Phase 2 Interventional

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

NCT00561366
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, Arimoclomol
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Pacific Palisades, California • San Francisco, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 19, 2026, 10:59 PM EDT
Terminated Phase 3 Interventional

Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)

NCT01016522
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
KetoCal
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 19, 2026, 10:59 PM EDT